Andersons pediatric cardiology 1683
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (60.63 KB, 3 trang )
320.DubocD,MeuneC,LereboursG,etal.Effectof
perindoprilontheonsetandprogressionofleft
ventriculardysfunctioninduchennemuscular
dystrophy.JAmCollCardiol.2005;45(6):855–
857.
321.SilvaMC,MeiraZMA,GurgelGiannettiJ,etal.
Myocardialdelayedenhancementbymagnetic
resonanceimaginginpatientswithmuscular
dystrophy.JAmCollCardiol.2007;49:1874–
1879.
322.EffectofmetoprololCR/XLinchronicheart
failure:metoprololCR/XLrandomised
interventiontrialincongestiveheartfailure
(MERIT-HF).Lancet.1999;353(9169):2001–
2007.
323.PackerM,FowlerMB,RoeckerEB,etal.Effect
ofcarvedilolonthemorbidityofpatientswith
severechronicheartfailure:resultsofthe
carvedilolprospectiverandomizedcumulative
survival(COPERNICUS)study.Circulation.
2002;106(17):2194–2199.
324.RusconiP,Gomez-MarinO,Rossique-Gonzalez
M,etal.Carvedilolinchildrenwith
cardiomyopathy:3-yearexperienceatasingle
institution.JHeartLungTransplant.
2004;23(7):832–838.
325.AlabedS,SabouniA,AlDakhoulS,BdaiwiY,
Frobel-MercierAK.Beta-blockersfor
congestiveheartfailureinchildren.Cochrane
DatabaseSystRev.2016;(1)[CD007037].
326.ShaddyRE,BoucekMM,HsuDT,etal.
Carvedilolforchildrenandadolescentswith
heartfailure:arandomizedcontrolledtrial.
JAMA.2007;298(10):1171–1179.
327.ReddyS,FungA,ManlhiotC,etal.Adrenergic
receptorgenotypeinfluencesheartfailure
severityandbeta-blockerresponseinchildren
withdilatedcardiomyopathy.PediatrRes.
2015;77(2):363–369.
328.MedinaE,SucharovCC,NelsonP,Miyamoto
SD,StaufferBL.Molecularchangesinchildren
withheartfailureundergoingleftventricular
assistdevicetherapy.JPediatr.2017;182:184–
189e181.
329.AlbersS,MeibohmB,MirTS,LaerS.
Populationpharmacokineticsanddose
simulationofcarvedilolinpaediatricpatients
withcongestiveheartfailure.BrJClin
Pharmacol.2008;65(4):511–522.
330.HommaS,ThompsonJL,PullicinoPM,etal.
Warfarinandaspirininpatientswithheart
failureandsinusrhythm.NEnglJMed.
2012;366(20):1859–1869.
331.HommaS,ThompsonJL,QianM,etal.Quality
ofanticoagulationcontrolinpreventingadverse
eventsinpatientswithheartfailureinsinus
rhythm:warfarinversusaspirininreduced
cardiacejectionfractiontrialsubstudy.Circ
HeartFail.2015;8(3):504–509.
332.ZiffOJ,LaneDA,SamraM,etal.Safetyand
efficacyofdigoxin:systematicreviewandmetaanalysisofobservationalandcontrolledtrial
data.BMJ.2015;351:h4451.
333.DigitalisInvestigationGroup.Theeffectof
digoxinonmortalityandmorbidityinpatients
withheartfailure.NEnglJMed.
1997;336(8):525–533.
334.RathoreSS,CurtisJP,WangY,BristowMR,
KrumholzHM.Associationofserumdigoxin
concentrationandoutcomesinpatientswith
heartfailure.JAMA.2003;289(7):871–878.
335.AhmedA,RichMW,LoveTE,etal.Digoxin
andreductioninmortalityandhospitalizationin
heartfailure:acomprehensiveposthocanalysis
oftheDIGtrial.EurHeartJ.2006;27(2):178–
186.
336.ClelandJG,DaubertJC,ErdmannE,etal.The
effectofcardiacresynchronizationonmorbidity
andmortalityinheartfailure.NEnglJMed.
2005;352(15):1539–1549.
337.AbrahamWT,FisherWG,SmithAL,etal.
